Recent Articles

June 24, 2015 8:39 am
Fenix Leung, DPhil, Oncology and Hematology Analyst, GlobalData
Data presented at the recent American Society of Clinical Oncology Annual Meeting 2015 by Bristol-Myers Squibb suggests that its Opdivo/Yervoy combination of immunotherapies to treat metastatic melanoma will shape the therapeutic landscape once it is approved. Read more...  
June 23, 2015 9:43 am
Cynthia Fox, Science Editor
By data-mining untapped clinician notes, Stanford University researchers found the heartburn drug class that includes Prilosec and Prevacid is associated with a small, but potentially significant, heart attack risk, even among the healthy, says a new study in PLOS One. Prilosec and Prevacid are proton pump inhibitors (PPIs). PPIs are the third-most prescribed drugs in the U.S. Read more...
June 22, 2015 9:01 am
Ryan Bushey, Associate Editor
China is a very lucrative pharmaceutical market, but the company is expected to appeal. Read more...
June 18, 2015 9:12 am
Joshua Libberton, Analyst, GBI Research
58 percent of drugs in the pancreatic cancer treatment pipeline are in the Discovery or Preclinical stages, 17 percent are in Phase 1 and 21 percent are in Phase 2, leaving just 4 percent of products in Phase 3 of development. Read more...
June 17, 2015 3:27 pm
Priscilla Velentgas, senior director of epidemiology, Quintiles Real-World and Late Phase Research; Ombretta Palucci, senior director, Real-World Evidence Strategy Unit, Quintiles Real-World and Late Phase Research
Under new draft guidance from the EMA, post-marketing studies of safety and effectiveness are required to be launched for seasonal influenza vaccines shortly after the beginning of the vaccination campaign each year. Based on this guidance, biopharma companies must take into account various operational, statistical and epidemiological elements in the planning of annual enhanced safety surveillance efforts. Read more...
June 17, 2015 10:06 am
Sheri Barnes, Ph.D., Study Director, Charles River
With cancer immunotherapy a major focus of oncology research over the past several years, a blockbuster drug will likely target the immune system. The industry is responding in kind by developing new tools that can be employed in this rapidly expanding field. One tool oncology researchers are exploring is actually not new at all—the murine tumor model. Read more...
June 15, 2015 3:06 pm
Seth Augenstein, Digital Reporter
Authorities are scrambling to control the spread of the illness, known fully as the Middle East Respiratory Syndrome. Read more...
June 15, 2015 8:33 am
Heather Leach, Ph.D., Immunology Analyst, GlobalData
The company’s latest report states that the US will cement its position as the largest of the seven major treatment markets (7MM) for axSpA. Read more...
June 12, 2015 10:09 am
Cynthia Fox, Science Editor
Statins, popular cholesterol lowering drugs, do not appear to cause short-term memory loss after all, according to a large recent study in JAMA Internal Medicine. The study, which looked at some one million patients, indicated past memory-loss reports may have been hampered by detection bias, as both statin users and users of non-statin lipid lowering drugs (LLDs) reported some memory loss. Read more...
June 10, 2015 2:35 pm
Ellie Gadd, Science Writer, LGC
Nanotechnologies are everywhere, from the medicines we take to the food we eat, but what do we really know about the potential effects when they come into contact with complex matrices and how do we ensure that nanoproducts are safe? The global market for nanomaterials is estimated by the European Commission to be...
Subscribe to Drug Discovery & Development